Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer

被引:44
作者
Honselmann, Kim C. [1 ,2 ,3 ]
Pergolini, Ilaria [1 ,2 ]
Fernandez-del Castillo, Carlos [1 ,2 ]
Deshpande, Vikram [1 ,2 ]
Ting, David [2 ,4 ]
Taylor, Martin S. [1 ,2 ]
Bolm, Louisa [3 ]
Qadan, Motaz [1 ,2 ]
Wellner, Ulrich [3 ]
Sandini, Marta [1 ,2 ]
Bausch, Dirk [3 ]
Warshaw, Andrew L. [1 ,2 ]
Lillemoe, Keith D. [1 ,2 ]
Keck, Tobias [3 ]
Ferrone, Cristina R. [1 ,2 ]
机构
[1] Massachusetts Gen Hosp, Dept Gastrointestinal Surg & Pathol, Boston, MA 02114 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Univ Med Ctr Schleswig Holstein, Dept Surg, Campus Luebeck, Lubeck, Germany
[4] Massachusetts Gen Hosp, MGH Canc Ctr, Boston, MA 02114 USA
关键词
lymph node status; PDAC; recurrence; survival; SHORT-COURSE CHEMORADIATION; PROTON-BEAM THERAPY; LONG-TERM SURVIVAL; DUCTAL ADENOCARCINOMA; NEOADJUVANT TREATMENT; PANCREATICODUODENECTOMY; CAPECITABINE;
D O I
10.1097/SLA.0000000000003123
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Our aim was to evaluate recurrence patterns of surgically resected PDAC patients with negative (pN0) or positive (pN1) lymph nodes. Summary Background Data: Pancreatic ductal adenocarcinoma (PDAC) is predicted to become the second leading cause of cancer death by 2030. This is mostly due to early local and distant metastasis, even after surgical resection. Knowledge about patterns of recurrence in different patient populations could offer new therapeutic avenues. Methods: Clinicopathologic data were collected for 546 patients who underwent resection of their PDAC between 2005 and 2016 from 2 tertiary university centers. Patients were divided into an upfront resection group (n = 394) and a neoadjuvant group (n = 152). Results: Tumor recurrence was significantly less common in pN0 patients as compared with pN1 patients, (upfront surgery: 55% vs. 77%,P< 0.001 and 64% vs. 78%,P= 0.040 in the neoadjuvant group). In addition, time to recurrence was significantly longer in pN0 versus pN1 patients in the upfront resected patients (median 16 mo pN0 vs. 10 mo pN1P< 0.001), and the neoadjuvant group (pN0 21 mo vs. 11 mo pN1,P< 0.001). Of the patients who recurred, 62% presented with distant metastases (63% of pN0 and 62% of pN1,P= 0.553), 24% with local disease (27% of pN0 and 23% of pN1,P= 0.672) and 14% with synchronous local and distant disease (10% of pN0 and 15% of pN1,P= 0.292). Similarly, there was no difference in recurrence patterns between pN0 and pN1 in the neoadjuvant group, in which 68% recurred with distant metastases (76% of pN0 and 64% of pN1,P= 0.326) and 18% recurred with local disease (pN0: 22% and pN1: 15%,P= 0.435). Conclusion: Time to recurrence was significantly longer for pN0 patients. However, patterns of recurrence for pN0 vs. pN1 patients were identical. Lymph node status was predictive of time to recurrence, but not location of recurrence.
引用
收藏
页码:357 / 365
页数:9
相关论文
共 18 条
  • [1] Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
    Callery, Mark P.
    Chang, Kenneth J.
    Fishman, Elliot K.
    Talamonti, Mark S.
    Traverso, L. William
    Linehan, David C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2009, 16 (07) : 1727 - 1733
  • [2] Classification of R1 resections for pancreatic cancer: the prognostic relevance of tumour involvement within 1 mm of a resection margin
    Campbell, Fiona
    Smith, Richard A.
    Whelan, Philip
    Sutton, Robert
    Raraty, Michael
    Neoptolemos, John P.
    Ghaneh, Paula
    [J]. HISTOPATHOLOGY, 2009, 55 (03) : 277 - 283
  • [3] Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression
    Crane, Christopher H.
    Varadhachary, Gauri R.
    Yordy, John S.
    Staerkel, Gregg A.
    Javle, Milind M.
    Safran, Howard
    Haque, Waqar
    Hobbs, Bridgett D.
    Krishnan, Sunil
    Fleming, Jason B.
    Das, Prajnan
    Lee, Jeffrey E.
    Abbruzzese, James L.
    Wolff, Robert A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) : 3037 - 3043
  • [4] Pancreatic adenocarcinoma: The actual 5-year survivors
    Ferrone, Cristina R.
    Brennan, Murray F.
    Gonen, Mithat
    Coit, Daniel G.
    Fong, Yuman
    Chung, Sun
    Tang, Laura
    Klimstra, David
    Allen, Peter J.
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (04) : 701 - 706
  • [5] Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for Locally Advanced and Borderline Resectable Pancreatic Cancer
    Ferrone, Cristina R.
    Marchegiani, Giovanni
    Hong, Theodore S.
    Ryan, David P.
    Deshpande, Vikram
    McDonnell, Erin I.
    Sabbatino, Francesco
    Santos, Daniela Dias
    Allen, Jill N.
    Blaszkowsky, Lawrence S.
    Clark, Jeffrey W.
    Faris, Jason E.
    Goyal, Lipika
    Kwak, Eunice L.
    Murphy, Janet E.
    Ting, David T.
    Wo, Jennifer Y.
    Zhu, Andrew X.
    Warshaw, Andrew L.
    Lillemoe, Keith D.
    Fernandez-del Castillo, Carlos
    [J]. ANNALS OF SURGERY, 2015, 261 (01) : 12 - 17
  • [6] Pancreatic ductal adenocarcinoma: Long-term survival does not equal cure
    Ferrone, Cristina R.
    Pieretti-Vanmarcke, Rafael
    Bloom, Jordan P.
    Zheng, Hui
    Szymonifka, Jackye
    Wargo, Jennifer A.
    Thayer, Sarah P.
    Lauwers, Gregory Y.
    Deshpande, Vikram
    Mino-Kenudson, Mari
    Fernandez-del Castillo, Carlos
    Lillemoe, Keith D.
    Warshaw, Andrew L.
    [J]. SURGERY, 2012, 152 (03) : S43 - S49
  • [7] Patterns, Timing, and Predictors of Recurrence Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma
    Groot, Vincent P.
    Rezaee, Neda
    Wu, Wenchuan
    Cameron, John L.
    Fishman, Elliot K.
    Hruban, Ralph H.
    Weiss, Matthew J.
    Zheng, Lei
    Wolfgang, Christopher L.
    He, Jin
    [J]. ANNALS OF SURGERY, 2018, 267 (05) : 936 - 945
  • [8] A Phase 1/2 and Biomarker Study of Preoperative Short Course Chemoradiation With Proton Beam Therapy and Capecitabine Followed By Early Surgery for Resectable Pancreatic Ductal Adenocarcinoma
    Hong, Theodore S.
    Ryan, David P.
    Borger, Darrell R.
    Blaszkowsky, Lawrence S.
    Yeap, Beow Y.
    Ancukiewicz, Marek
    Deshpande, Vikram
    Shinagare, Shweta
    Wo, Jennifer Y.
    Boucher, Yves
    Wadlow, Raymond C.
    Kwak, Eunice L.
    Allen, Jill N.
    Clark, Jeffrey W.
    Zhu, Andrew X.
    Ferrone, Cristina R.
    Mamon, Harvey J.
    Adams, Judith
    Winrich, Barbara
    Grillo, Tarin
    Jain, Rakesh K.
    DeLaney, Thomas F.
    Fernandez-del Castillo, Carlos
    Duda, Dan G.
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 89 (04): : 830 - 838
  • [9] PHASE I STUDY OF PREOPERATIVE SHORT-COURSE CHEMORADIATION WITH PROTON BEAM THERAPY AND CAPECITABINE FOR RESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA OF THE HEAD
    Hong, Theodore S.
    Ryan, David P.
    Blaszkowsky, Lawrence S.
    Mamon, Harvey J.
    Kwak, Eunice L.
    Mino-Kenudson, Mari
    Adams, Judith
    Yeap, Beow
    Winrich, Barbara
    DeLaney, Thomas F.
    Fernandez-Del Castillo, Carlos
    [J]. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 79 (01): : 151 - 157
  • [10] Retrospective cohort analysis of neoadjuvant treatment and survival in resectable and borderline resectable pancreatic ductal adenocarcinoma in a high volume referral centre
    Itchins, M.
    Arena, J.
    Nahm, C. B.
    Rabindran, J.
    Kim, S.
    Gibbs, E.
    Bergamin, S.
    Chua, T. C.
    Gill, A. J.
    Maher, R.
    Diakos, C.
    Wong, M.
    Mittal, A.
    Hruby, G.
    Kneebone, A.
    Pavlakis, N.
    Samra, J.
    Clarke, S.
    [J]. EJSO, 2017, 43 (09): : 1711 - 1717